Tarantelli, Chiara Lupia, Antonio Stathis, Anastasios Bertoni, Francesco 2020-02-05 The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti- cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold. application/pdf https://susi.usi.ch/global/documents/319051 https://n2t.net/ark:/12658/srd1319051 https://susi.usi.ch/documents/319051/files/Bertoni_ijms_2020.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21031060 info:eu-repo/semantics/altIdentifier/ark/12658/srd1319051 info:eu-repo/semantics/openAccess CC BY International journal of molecular sciences. - 2020, vol. 21, no. 3, p. 21 p TORC1 TORC2 PI3K Lymphoma Chronic lymphocytic leukemia info:eu-repo/classification/udc/61 Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma? http://purl.org/coar/resource_type/c_6501